1. DOP37 Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study. (30th January 2023) Authors: Danese, S; Abreu, M T; Wolf, D C; Canavan, J B; Jain, A; Wu, H; Petersen, A; Charles, L; Panaccione, R; Afzali, A Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i101 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DOP44 Long-term use of ozanimod in patients with moderately to severely active Ulcerative Colitis. (21st January 2022) Authors: Danese, S; Colombel, J F; Ponich, T; Jovanovic, I; Bossuyt, P; Longman, R; Alekseeva, O; Petersen, A; Chitkara, D; Marta, C; Charles, L; Rubin, D T; Afzali, A; Loftus, E V; Wolf, D C Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i093 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. DOP45 Long-term cardiac safety of ozanimod in phase 3 clinical program of Ulcerative Colitis and relapsing multiple sclerosis. (21st January 2022) Authors: Armuzzi, A; Cross, R K; Lichtenstein, G; Calkwood, J; Pai, A; Pondel, M; Ahmad, H A; Charles, L; Elegbe, A; Petersen, A; Sheffield, J K; Javed, A; Hou, J; Regueiro, M; Wolf, D C; Long, M Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i094 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P187 Change in Urgency Status Among Ulcerative Colitis Patients: Understanding the Impact of Treatment Changes from the Corrona Inflammatory Bowel Disease Registry. (27th May 2021) Authors: Wolf, D C; Naegeli, A N; Moore, P C; Janak, J C; Crabtree, M M; Shan, M; Hunter, T M; Sontag, A; Cross, R K Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S256 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P405 Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension. (30th January 2023) Authors: Panaccione, R; Danese, S; Wolf, D C; Canavan, J B; Jain, A; Wu, H; Petersen, A; Charles, L; Afzali, A; Abreu, M T Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i534 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P464 Effects of ozanimod on histologic remission and mucosal healing over 3 years of continuous treatment in patients with ulcerative colitis. (30th January 2023) Authors: Panaccione, R; Danese, S; Wolf, D C; Canavan, J B; Jain, A; Wu, H; Petersen, A; Afzali, A; Abreu, M T Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i591 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P544 Histological remission following ozanimod treatment is associated with concurrent clinical remission and endoscopic mucosal healing: Results from the TOUCHSTONE study. (16th January 2018) Authors: Feagan, B G; Sandborn, W J; D'Haens, G; Pai, R K; Hanauer, S B; Wolf, D C; Vermeire, S; Ghosh, S; Levesque, B G; Shan, K; Aranda, R; Liu, W J; Olson, A Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S381 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P632 Etrasimod induction therapy in moderately to severely active Crohn's disease: results from a phase 2, randomised, double-blind substudy. (30th January 2023) Authors: D'Haens, G; Dubinsky, M C; Peyrin-Biroulet, L; Danese, S; Sands, B E; Wolf, D C; Yarur, A; Chiorean, M; Dray, D; Modesto, I; Tan, H; Gu, G; Lopez, C; Su, C; Zhang, J; Cataldi, F; McDonnell, A; Schreiber, S; Feagan, B G; Vermeire, S Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i764 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P687 Clinical remission demonstrated with oral ozanimod in the overall population and across multiple subgroups of patients with moderately to severely active ulcerative colitis in the TOUCHSTONE trial. (25th January 2019) Authors: Feagan, B G; Sandborn, W J; D'Haens, G; Hanauer, S; Wolf, D C; Vermeire, S; Ghosh, S; Petersen, A; Hua, S Y; Shan, K; Liu, J Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S464 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P719 Symptomatic improvement and long-term stability of ulcerative colitis symptoms over 3 years of ozanimod treatment. (30th January 2023) Authors: Danese, S; Abreu, M T; Afzali, A; Canavan, J B; Jain, A; Wu, H; Petersen, A; Panaccione, R; Wolf, D C Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i848 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗